PrintThe Burrill Report
The Burrill Report (February 21, 2011): Why Pharma's Future Will Be Selling Results (.MP3,14.21 Mb)
Pharmaceutical companies need to prepare for a new world in which instead of getting paid for drugs, they will be paid for outcomes. So argues Ernst & Young in its latest annual report on the pharmaceutical industry. We spoke to Carolyn Buck Luce, Global pharmaceutical sector leader for Ernst & Young, about how changes to the healthcare landscape and a shift in power to payors is opening the door to non-traditional healthcare companies, forcing pharmaceutical companies to develop digital health strategies, and changing the very idea of what it means to be a drug company today.
February 17, 2011
http://www.burrillreport.com/article-why_pharmas_future_will_be_selling_results.html
BUSINESS STRATEGY
Why Pharma's Future Will Be Selling Results
Podcast: February 21, 2011[Please login to post comments]
- Astellas strikes $1.3B Cancer Deal with Aveo
Stronger ties support both partners’ ambitions. Read More - It's a Deal
Sanofi-Aventis will make Genzyme its rare disease center of excellence. Read More - Failure is the Norm
Study sheds new light on U.S. drug approval rates. Read More - Hard Hit to Soft Drinks
Caramel coloring in colas and other dark beverages may contain carcinogens. Read More - Paying Attention to Neglected Diseases
Greater investment being made, but funding shifts away from products to basic research as public sector plays a greater role. Read More - A Generic Argument
Obama budget seeks to speed the entry to market for generic drugs and biosimilars. Read More - Budget Increases Proposed for Health Agencies
FDA, NIH, NSF budgets grow in Obama proposal. Read More - Merck Serono Withdraws EMEA Application to Market Oral MS Drug
The weekly round-up of failed trials, missed targets, and other business mishaps. Read More - Biotech back in the positive column
For the week ending February 11, 2011 Read More - Gevo Goes Public
Renewable chemicals and fuels maker raises $107 million. Read More
.gif)
- Sanofi to Buy Genzyme for Sweetened $20.1 Billion After Nine-Month Pursuit
Bloomberg - For Cold Virus, Zinc May Edge Out Even Chicken Soup
The New York Times - Ecuadorean Villagers May Hold Secret to Longevity
The New York Times - Obama budget targets brand name medicines
Reuters - Medical Device Makers Shun United States
The New York Times - Drugmakers’ Fever for the Power of RNA Interference Has Cooled
The New York Times - Genzyme, Sanofi boards to meet on Sunday -sources
Reuters - States Diverge on How to Deal With Health Care Ruling
The New York Times - Medical Detectives Find Their First New Disease
The New York Times - Federal Judge Rules Health Law Violates Constitution
The New York Times